STAT

Can MRD testing reshape adjuvant and surveillance decisions in cancer care?

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
The American Journal of Managed Care

MRD Testing Could Cut Costs, Refine Blood Cancer Care: Ravi Vij, MD, MBA

Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity. Measurable residual disease (MRD ...
CURE

Blood Test May Help Older Patients With Breast Cancer Safely Avoid Surgery

A new study shows Signatera ctDNA testing may identify older patients with ER+/HER2- breast cancer who can manage their care ...
Nasdaq

Myriad Genetics Unveils Promising Clinical Data on Precise MRD Test for Oligometastatic Clear-Cell Renal Cell Carcinoma at AACR Annual Meeting

Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...

Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year.
Cure Today

What MRD Testing Can Mean for Patients With Breast Cancer and Survivors

Minimal residual disease testing can offer psychological comfort to patients and survivors as well as insight into potential treatment strategies for care providers. Minimal residual disease, or MRD, ...
Seeking Alpha

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR Tracer ...
Morningstar

Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk

Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...
Morningstar

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group ...
MarketWatch

Invivoscribe(R) Launches LeukoStrat(R) KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat(R) KMT2A + MRD Assay and Software to its industry-leading ...
The American Journal of Managed Care

Leveraging MRD Testing to Advance Value-Based Care in Multiple Myeloma: Emilie Aschenbrenner, PharmD, BCOP

Emilie Aschenbrenner, PharmD, BCOP, highlights how measurable residual disease (MRD) testing can support value-based care in multiple myeloma by guiding personalized treatment intensity, potentially ...